HLA-C and diffuse large B-cell lymphoma: In DLBCL, the majority of bispecific antibodies currently in advanced clinical development target CD20 on B cells and CD3 of the TCR complex, bypassing MHC/TCR binding and resulting in T‐cell engagement.51